Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Anders Davidson

Vascular Surgery Travis Afb, CA Medical Doctor

NPI 1881957694 CMS profile 8801531

101 Bodin Cir, Travis Afb, CA 94535

Open in the dashboard

General payments

$7,043

52 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anders Davidson of Travis Afb, CA is reported in the CMS Open Payments database as having received $7,043 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $585 7
2024 General $1,072 11
2023 General $2,997 11
2022 General $1,874 19
2021 General $323 3
2020 General $191 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anders Davidson
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Anders Davidson were reported at $585. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Anders Davidson Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $191 $348 $118–$1,110 $114
2021 $323 $471 $158–$1,421 $132
2022 $1,874 $725 $222–$2,183 $149
2023 $2,997 $836 $257–$2,440 $160
2024 $1,072 $909 $252–$2,619 $164
2025 $585 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AngioDynamics, Inc. $1,824 1 payment
  2. W. L. Gore & Associates, Inc. $1,444 15 payments
  3. Silk Road Medical, Inc. $1,269 8 payments
  4. Medtronic, Inc. $900 8 payments
  5. Boston Scientific Corporation $477 5 payments
  6. Terumo Medical Corporation $261 3 payments
  7. Medtronic Vascular, Inc. $191 1 payment
  8. Penumbra, Inc. $157 1 payment
  9. LeMaitre Vascular, Inc. $130 2 payments
  10. Prytime Medical Devices, Inc. $102 1 payment
  11. Other $288 7 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,028 50 payments
  2. Debt forgiveness $1,824 1 payment
  3. Education $191 1 payment
Products named General payments · program years 2020–2025
  1. Auryon Atherectomy Catheter 0.9 mm OTW $1,824 1 payment
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,269 8 payments
  3. ENROUTE Transcarotid Stent $1,269 8 payments
  4. ENDURANT IIS $636 5 payments
  5. EXCLUDER Conformable AAA Endoprosthesis with Active Control $441 5 payments
  6. GORE TAG Thoracic Branch Endoprosthesis $312 2 payments
  7. ELUVIA $308 3 payments
  8. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $305 2 payments
  9. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $305 2 payments
  10. Azur CX Detachable $261 3 payments
  11. Other $2,379 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Vascular Surgery: 122

Drug cost

$169

Median for Vascular Surgery: $14,135

Branded share of claims

0%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 13 $169

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$29,479

Medicare's payments for the services billed

Medicare patients

286

Average age 74

Services billed

460

125 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Heart failure 47%
Ischemic heart disease 47%
Chronic kidney disease 47%
Diabetes 45%
Atrial fibrillation 34%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record